Neurology

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, discussed what attendees can expect at the 2025 MDA Meeting.

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.

The chief medical advisor of the Muscular Dystrophy Association also shared his thoughts on the 75th anniversary of the organization.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

With regard to safety, the company stated that no new safety signals have been reported.

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

The company has begun the process of randomly assigning enrolled participants in the sham-controlled phase 2 REGENERATE-PD trial.

We've compiled a list of 5 clinical trials with expected data readouts in 2025 that are worth keeping an eye on.

Review top news and interview highlights from the week ending January 24, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SGT-212, a dual route gene transfer therapy, is intended to be delivered both by intradentate nucleus infusion and IV infusion at the same time.

CGTLive® took a closer look at the first-in-human clinical trial for the next-generation gene therapy.

Review top news and interview highlights from the week ending January 17, 2025.

The CGTLive® team highlights 5 therapeutics with PDUFA dates or other FDA actions likely in 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending January 10, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ultragenyx is seeking accelerated approval for the BLA based on the use of CSF heparan sulfate data from the phase 1/2/3 Transpher A clinical trial.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

In 2024, CGTLive spoke with experts at various medical conferences to seek their insight on the data they presented and more.

Review top news and interview highlights from the weeks ending December 27, 2024, and January 3, 2025.

The company requested priority review for the BLA.

Take a look what stood out as pillars of progress and success from all of CGTLive's most popular neurology stories in 2024.

In 2024, CGTLIve spoke with experts outside the context of the conference cycle to seek their insight on company announcements, pipeline therapies, and disease awareness, among other topics.